Cookies

Like most websites The Analytical Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Business & Education Business

Business in Brief

Amplifying automation

Waters has announced its acquisition of Andrew Alliance – an innovator in specialty laboratory automation technology – broadening their product portfolio to include advanced robotics. The software from Andrew Alliance, which uses a cloud-native platform and modern interface, could improve laboratory workflow performance and repeatability.

Shine bright like an emerald

Emerald Scientific customers in North America can now take advantage of PerkinElmer’s high-throughput instruments and regulation-compliant software for cannabis and hemp testing, following announcement of collaboration between the two companies. On top of gaining access to advanced LC-MS, GC-MS, high-performance LC and microwave sample separation systems, Perkin Elmer’s services and consumables (chromatography columns, vials, preparation products and so on) will also be on offer.

Translating Success

Clarivate Analytics has signed an agreement to acquire Decision Resources Group (DRG; a healthcare data and analytics body) from Piramal Enterprises Limited for $950 million. The partnership will be well-positioned to support customers across the entire drug, device and medical technology lifecycle, from research to patient outcomes, in the ever-expanding market of life science analytics – currently worth $19 billion.

Don’t mess with Michigan

Attorney general of Michigan, Dana Nessel, is suing 17 of the nation’s biggest chemical manufacturers for $3 million over the production and “intentional hiding” of per- and polyfluoroalkyl substances (PFAS), which have been linked to diseases, including cancer. Companies have been told to cease PFAS sales and offer compensation for any subsequent investigation, monitoring or removal required.

Driving drug discovery forward

ZebiAI Therapeutics and X-Chem have entered a strategic agreement to enable the validation of therapeutic targets and accelerate drug candidate discovery. X-Chem’s proprietary DNA Encoded Library technology (DEX) will support ZebiAi’s quest to discover small molecules to support its Chemome Initiative, which is focused on the identification of probe molecules for novel targets, driving drug candidate identification.

Enjoy our FREE content!

Log in or register to gain full unlimited access to all content on the The Analytical Scientist site. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Analytical Scientist magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

Register to The Analytical Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Analytical Scientist magazine

Register